Let me start with the second one, the investor rights issue.
There are many dimensions to it. On the whole question of the number of countries that now would be in a position to sue Canada, it would be greatly extended. Currently it's our NAFTA partners, so we're adding I think another 10 countries to that list, which obviously will mean a lot more lawsuits. That's one element of it.
The Eli Lilly $500-million lawsuit is one that we should be very worried about. Eli Lilly is not suing primarily under TRIPS; it's trying to overturn a Federal Court decision in Canada that had invalidated two patents it had. It's trying to do that by creating the idea that the patents it was applying for were essentially an investment. That has not been done before under NAFTA.
The TPP would effectively enable companies like that to treat them like investments. That opens the door to lots of new lawsuits like the Lilly one. The Lilly one is not yet resolved, but it's very worrisome if that's the case. We should be very concerned about that, and we should be concerned that the TPP does not include provisions that would give all of those companies the same kind of rights that Eli Lilly is trying to establish through its NAFTA challenge.